SOUTHEASTERN CANCER STUDY GROUP

东南癌症研究小组格兰特描述了临床研究 教职员工的活动、科学和教育贡献 佛罗里达大学。我们需要资金来支持我们在 旨在改善癌症预后的合作临床试验 治疗。该机构在 东南部癌症研究小组在以下领域：白血病， 淋巴瘤，骨髓移植，新药开发，以及 免疫疗法。外科、内科肿瘤学、病理学和 放射治疗在很大程度上促进了在 东南部癌症课题组的临床研究。在以下方面努力 方案设计将侧重于具有治疗意图的多模式治疗 适用于早期疾病患者以及新药的临床试验 晚期疾病患者的发展。这个机构将 继续执行与整个团队一致的小规模试点研究 努力，并将合作开发适当的试验性研究 全组临床试验。把主要精力投向发展 自体和异基因骨髓移植的疗效 治疗适当的肿瘤疾病的方法。药理和 放射性生物研究将旨在提高安全和 骨髓移植的疗效。这个机构带来了特殊的 作为基础的对全组肿瘤生物学工作的专业知识和承诺 用于临床研究。免疫诊断机构是整个集团的 所需的实验室设施，以充分研究 生物反应调节剂将发挥越来越重要的作用 作为抗肿瘤药物和细胞毒治疗的辅助剂。 机构成员是淋巴瘤委员会、肿瘤委员会的主席 免疫学委员会和第二阶段委员会。12名成员是 积极参与16个委员会，主持22个集团范围的协议。这 该机构正在为发展 计算机化数据管理系统(CPIS)作为第一个非现场测试 中间。最近安装的核磁共振扫描仪 将允许这家机构带来适当的新的肿瘤诊断 临床试验的参数。面向社会的制度取向 精心设计的东南部癌症生物学合理的临床试验 学习集团将为一流的患者护理做出贡献 所有肿瘤学方面的医学生、住院部官员和团契培训 纪律。

The Southeastern Cancer Study Group Grant describes clinical investigative activities, scientific, and educational contributions of the faculty at the University of Florida. Funds are requested to support our effort in cooperative clinical trials designed to improve the outcome of cancer treatment. This Institution has taken a leadership role within the Southeastern cancer Study Group in the following areas: leukemia, lymphoma, bone marrow transplantation, new drug development, and immunotherapy. Expertise in surgery, medical oncology, pathology and radiotherapy have contributed substantially to the successful efforts in clinical investigation of the Southeastern cancer Study Group. Efforts in protocol design will focus on multi-modality treatment with curative intent for patients with early disease as well as clinical trials for new drug development in patients with advanced disease. This institution will continue to execute small pilot studies consistent with the overall group effort and will collaborate in developing appropriate pilot studies for group-wide clinical trials. Major effort will be directed to development of both autologous and allogeneic bone marrow transplantation as curative approaches to appropriate neoplastic diseases. Pharmacologic and radio-biological research will be designed to improve the safety and efficacy of bone marrow transplantation. This institution brings special expertise and committment to group-wide efforts in tumor biology as a basis for clinical research. Immunodiagnostic facilities are a group-wide resource as are the laboratory facilities required to study adequately the biological response modifiers which will play and increasingly important role as anti-tumor agents and adjunctive agents to cytotoxic therapy. Institutional members are Chairmen of the Lymphoma Committee, the Tumor Immunology Committee, and the Phase II Committee. Twelve members are active in 16 committees and chair 22 group-wide protocols. This institution is making a significant contribution to the development of a computerized data management system (CPIS) as the first off-site test center. The recent installation of a nuclear magnetic resonance scanner will permit this institution to bring appropriate new tumor diagnostic parameters to clinical trials. The institutional orientation towards the well designed biologically sound clinical trials of the Southeastern Cancer Study Group will contribute to excellent patient care as well as superb medical student, house officer, and fellowship training in all oncologic disciplines.